ORIC Pharmaceuticals, Inc. Share Price & Technical Analysis
ORIC · $8.45 (+1.56%)
Healthcare / Biotechnology
$8.45
+1.56%
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target …
Price chart
Seasonality
May has 2 positive and 2 negative years (last 5 years shown)
-16% return in May, 14% avg return in past 3 year May month.
34% return in 2026, 42% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 26% | 30% | -3% | -3% | -16% | – | – | – | – | – | – | – | 34% |
| 25 | 27% | -22% | -31% | 4% | 44% | 23% | -1% | 5% | 18% | 13% | -9% | -29% | 41% |
| 24 | 21% | 14% | 1% | -36% | 2% | -22% | 58% | -7% | 0% | -7% | 4% | -18% | 11% |
| 23 | -2% | -23% | 30% | -9% | -4% | 53% | 9% | 7% | -33% | 12% | 18% | 16% | 75% |
| 22 | -32% | -21% | -33% | -41% | 0% | 32% | -18% | -5% | -6% | -18% | 33% | 64% | -45% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$927.52M
P/E ratio
—
52W high
$14.93
52W low
$5.51
Volume
1,27,153
Beta
1.10
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is ORIC Pharmaceuticals, Inc. share price today?
- ORIC Pharmaceuticals, Inc. (ORIC) last traded around $8.45 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ORIC have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ORIC. Download the app for real-time alerts.
- How can I analyze ORIC Pharmaceuticals, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.